GSK claims that Pfizer’s FDA-approved vaccine for respiratory syncytial virus infringes on four patents protecting its own approved vaccine, Arexvy. The patent suit comes with the RSV season approaching.
GSK Patent Suit Aims to Halt Pfizer’s RSV Vaccine for Adults, But Not Infants
